# Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

> **NCT04661033** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 8 (actual)

## Conditions studied

- Warm Autoimmune Hemolytic Anemia (wAIHA)

## Interventions

- **DRUG:** Isatuximab SAR650984

## Key facts

- **NCT ID:** NCT04661033
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-09
- **Primary completion:** 2023-06-26
- **Final completion:** 2023-06-26
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Study discontinuation based on strategic sponsor decision; not driven by any safety concerns.
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661033, "Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04661033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*